De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.
about
Leucine zipper domain is required for Kaposi sarcoma-associated herpesvirus (KSHV) K-bZIP protein to interact with histone deacetylase and is important for KSHV replicationMutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphomaActivation and repression of Epstein-Barr Virus and Kaposi's sarcoma-associated herpesvirus lytic cycles by short- and medium-chain fatty acidsA locus encompassing the Epstein-Barr virus bglf4 kinase regulates expression of genes encoding viral structural proteinsGlucocorticoids activate Epstein Barr virus lytic replication through the upregulation of immediate early BZLF1 gene expression.Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated MalignanciesHistone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors.Valpromide Inhibits Lytic Cycle Reactivation of Epstein-Barr Virus.Role of RNF4 in the ubiquitination of Rta of Epstein-Barr virus.Proteomic analysis reveals selective impediment of neuronal remodeling upon Borna disease virus infection.Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report.Nucleoside diphosphate kinase/Nm23 and Epstein-Barr virus.A critical Sp1 element in the rhesus rhadinovirus (RRV) Rta promoter confers high-level activity that correlates with cellular permissivity for viral replication.Histone modifications in herpesvirus infections.Histone deacetylases in viral infections.Recent advances in the study of Kaposi's sarcoma-associated herpesvirus replication and pathogenesis.Epigenetic Pathways of Oncogenic Viruses: Therapeutic Promises.Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin.Epigenetics and Genetics of Viral Latency.Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells.Valproic acid antagonizes the capacity of other histone deacetylase inhibitors to activate the Epstein-barr virus lytic cycle.Cellular immediate-early gene expression occurs kinetically upstream of Epstein-Barr virus bzlf1 and brlf1 following cross-linking of the B cell antigen receptor in the Akata Burkitt lymphoma cell line.Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitorsStimulus duration and response time independently influence the kinetics of lytic cycle reactivation of Epstein-Barr virus.Kaposi sarcoma-associated herpes virus (KSHV) G protein-coupled receptor (vGPCR) activates the ORF50 lytic switch promoter: a potential positive feedback loop for sustained ORF50 gene expressionThe Role of Epigenetic Regulation in Epstein-Barr Virus-Associated Gastric Cancer.Dynamic chromatin environment of key lytic cycle regulatory regions of the Epstein-Barr virus genome.Decitabine inhibits tumor cell proliferation and up-regulates e-cadherin expression in Epstein-Barr virus-associated gastric cancer.Tousled-like kinases modulate reactivation of gammaherpesviruses from latency.
P2860
Q24307542-B7765C54-9088-4A70-8AB2-6226BB26E0D0Q28472086-DCACFC0A-5AD5-4187-AF3C-42FF3E7CAB85Q33900360-E3B7EDB7-050B-4CBA-8F6B-D2BBF378BF45Q34105467-EF3CD8B7-FC25-4838-9503-9B2211A00925Q34126659-681F3034-A8DC-4334-9B37-0818136B959BQ35829978-EA506F5F-5B82-41A6-B2BD-4F6221F37A59Q36594092-2F575185-A480-42D8-9088-732878471ADCQ36736242-322B0AB8-EF99-425F-B7E3-3DC6C09CC8AAQ36812436-C9D5F00A-2B04-45D9-AC23-FCED86227774Q36994622-09CE7474-A12A-4724-AA87-F2386292CC78Q37406827-6B7ADD9B-6BFC-4AD0-A00C-DF6CED98428FQ37468665-89D495A0-7D8E-4BDC-896E-3A460B0D10C3Q37523519-3A36326F-EADB-4B8A-B1D5-7C2F659FBE17Q37970405-9A025581-6DDC-41C6-913C-F920118A7103Q38019133-ABD69B70-13A8-4392-ABA9-71E16F3DC2A3Q38449592-4EF75C0E-5B7A-4C16-BC7F-977898A9B6E8Q38692795-1DABD254-6F71-4F37-99A0-FF3F9998B634Q38812282-59C91F66-1ECE-4B9F-BBD2-CBDAD10931AEQ38833222-EF6E9064-6CFA-4069-9FA4-197ABA85297AQ39392105-1056EE93-B3E1-4734-BE34-444CAEED4B79Q39575256-0C0C9403-6311-468B-BE7B-A00666FD010BQ39652746-62F32F88-9928-46BB-B4F4-D8475B1A3AA6Q39778922-FE1311A0-88B7-4C75-8213-328DC8250E30Q39816440-FC1995E2-6B7E-4ACB-B367-06039FA409FEQ39819343-A685A6B6-85F9-41D8-8AE1-40D1E2BB3DC3Q40102087-BE4F3544-EF27-42A8-A971-8C87CE9B8DFFQ40605557-21687402-F3B9-4E88-B8EC-C70A1E3DC662Q40608955-AE16568C-625D-4DFF-930E-52F69028D790Q42274743-01B2DE22-E833-4204-9D2C-72512288C248
P2860
De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
De novo protein synthesis is r ...... and protein kinase C agonists.
@en
type
label
De novo protein synthesis is r ...... and protein kinase C agonists.
@en
prefLabel
De novo protein synthesis is r ...... and protein kinase C agonists.
@en
P2093
P2860
P356
P1433
P1476
De novo protein synthesis is r ...... and protein kinase C agonists.
@en
P2093
Derek Daigle
George Miller
Jianjiang Ye
Lyndle Gradoville
P2860
P304
P356
10.1128/JVI.00982-07
P407
P577
2007-06-27T00:00:00Z